Collegium Pharmaceutical (COLL) News Today $23.23 +0.23 (+1.00%) Closing price 04:00 PM EasternExtended Trading$22.77 -0.46 (-1.98%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Collegium Pharmaceutical Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocksOctober 26 at 9:43 PM | finance.yahoo.comQ2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ: COLL) vs the rest of the branded pharmaceuticals stocksOctober 26 at 11:42 AM | msn.comComparing Collegium Pharmaceutical (NASDAQ:COLL) and Journey Medical (NASDAQ:DERM)October 26 at 4:29 AM | americanbankingnews.comCollegium to Report Third Quarter 2026 Financial Results on November 5, 2026October 22, 2026 | globenewswire.comCollegium Pharmaceutical IncOctober 21, 2026 | money.usnews.comCollegium Pharmaceutical Announces Seven ADHD Abstracts Accepted for AACAP and NEI Fall CongressesOctober 21, 2026 | quiverquant.comQCollegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall CongressesOctober 21, 2026 | globenewswire.comCollegium Pharmaceutical Settles Nucynta Patent Litigation for $17 MillionOctober 19, 2026 | marketscreener.comMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Average Price Target of $48.71 According to BrokeragesOctober 18, 2026 | americanbankingnews.comCollegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance CutOctober 17, 2026 | seekingalpha.comCollegium Pharmaceutical (NASDAQ:COLL) Upgraded at Zacks ResearchOctober 17, 2026 | marketbeat.comCollegium Pharmaceutical (COLL) Receives a Buy from BarclaysOctober 16, 2026 | theglobeandmail.comCollegium Pharmaceutical (NASDAQ:COLL) Stock Jumps 4.1% - Time to Buy?October 14, 2026 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71October 13, 2026 | marketbeat.comCollegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer SaysOctober 9, 2026 | finance.yahoo.comZacks Research Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Strong SellOctober 8, 2026 | marketbeat.comCollegium Pharmaceutical, Inc. Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeOctober 6, 2026 | marketscreener.comMCollegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeOctober 6, 2026 | globenewswire.comCollegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low - Should You Sell?September 29, 2026 | marketbeat.comCollegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer SaysSeptember 23, 2026 | finance.yahoo.comOppenheimer initiates coverage of Collegium Pharmaceutical with outperformSeptember 23, 2026 | msn.comH.C. Wainwright Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)September 22, 2026 | theglobeandmail.comCollegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comLeerink Partners initiates coverage of Collegium Pharmaceutical with outperformSeptember 10, 2026 | msn.comTruist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy RatingSeptember 9, 2026 | marketscreener.comMLeerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price TargetSeptember 9, 2026 | marketscreener.comMCollegium to Participate in Upcoming Investor ConferencesSeptember 8, 2026 | globenewswire.comCollegium Pharmaceutical, Inc. (COLL)September 4, 2026 | finance.yahoo.comA Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39August 28, 2026 | gurufocus.comCollegium CEO is moving the biotech firm to Boston from the suburbsAugust 24, 2026 | bostonglobe.comBBarclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)August 20, 2026 | theglobeandmail.comCollegium Pharmaceutical (COLL) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comCollegium gains on $50M accelerated share buyback programAugust 13, 2026 | msn.comCollegium Pharmaceutical Launches $50 Million Accelerated Share BuybackAugust 13, 2026 | tipranks.comCollegium Announces $50 Million Accelerated Share Repurchase ProgramAugust 13, 2026 | globenewswire.com5 revealing analyst questions from Collegium Pharmaceutical’s Q2 earnings callAugust 13, 2026 | msn.comCollegium Pharmaceutical, Inc. Q2 2026 Earnings Call SummaryAugust 7, 2026 | finance.yahoo.comCOLL Q2 deep dive: ADHD expansion and pain business headwinds shape guidanceAugust 7, 2026 | msn.comCollegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 7, 2026 | seekingalpha.comCollegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comCollegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock DropsAugust 6, 2026 | theglobeandmail.comCollegium Pharmaceutical Reports Q2 2026 Results, Completes AZSTARYS Acquisition and Raises Full-Year GuidanceAugust 6, 2026 | quiverquant.comQCollegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company ProgressAugust 6, 2026 | globenewswire.comCollegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-RatingAugust 1, 2026 | seekingalpha.comWinners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals StocksJuly 27, 2026 | finance.yahoo.comCollegium to Report Second Quarter 2026 Financial Results on August 6, 2026July 23, 2026 | globenewswire.comNewly upgraded One Lincoln tower lands its first biotech tenantJuly 21, 2026 | bostonglobe.comBDivcoWest Welcomes Collegium Pharmaceutical to One LincolnJuly 20, 2026 | businesswire.comCollegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in BostonJuly 20, 2026 | globenewswire.comIs Collegium Pharmaceutical (COLL) Still Undervalued As Its Growth Narrative Holds Up?July 20, 2026 | finance.yahoo.com Collegium Pharmaceutical Media Mentions By Week Collegium Pharmaceutical Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COLL News Sentiment▼-0.120.68▲Average Healthcare News Sentiment Collegium Pharmaceutical News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COLL Articles This Week▼54▲COLL Articles Average Week Collegium Pharmaceutical Trends on MarketBeatThis week vs. last weekNew Followers1Searches2-33%Page Views1,607-14% Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies HCM News Today BHC News Today SUPN News Today MBX News Today PBH News Today PRGO News Today HRMY News Today TRLV News Today XERS News Today MLYS News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Collegium Pharmaceutical dated 10/26/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredElon gets it. Do you?Moderna shares surged almost 200% in a single day after a successful phase 3 trial for its cancer drug, while ...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThink you missed the gold bull market? Read this…Gold sits roughly 19% below its January record, yet mining stocks remain historically under-owned. Mining n...Golden Portfolio | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
